
|Videos|January 20, 2021
Role of PARP Inhibition in Recurrent Ovarian Cancer
Author(s)Thomas Herzog, MD
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Debating CAR T-Cell Therapy Vs Bispecifics at First Relapse in Myeloma
2
Perioperative Durvalumab Combo Boosts Survival in Resectable Gastric Cancer
3
FDA Gives Accelerated Approval to Sevabertinib in HER2+ NSCLC
4
FLT3 Inhibitor Strategies Continue to Improve Survival Across AML Settings
5
























































